Biosimilar debate focuses on key lawmaker

Palo Alto Democrat Rep. Anna Eshoo has been a key sponsor of the bill backing 12 years of data exclusivity for biologics, a position dearly loved by the 2,000 biomedical companies in California. But her position that the bill is a boon for consumers, establishing a pathway for biosimilar approvals that doesn't currently exist, has come under fierce attack from a variety of analysts who say Eshoo is simply helping to ensure that biologic prices remain sky high. Report [1]